New England Biolabs Expands Epigenomics Partnership with EpiCypher
Event summary
- New England Biolabs (NEB) and EpiCypher expanded their strategic partnership on May 19, 2026, to co-develop next-generation epigenomics research tools.
- NEB will distribute EpiCypher's CUTANA portfolio in key international markets, starting with Germany and the UK.
- The collaboration builds on existing joint developments, including CUT&RUN, CUT&Tag, and NiCE-seq solutions, supported in part by NIH SBIR funding.
- EpiCypher's CUTANA Fiber-seq kit integrates NEB reagents, accelerating its market launch.
The big picture
The expanded partnership between NEB and EpiCypher underscores the growing importance of epigenomics in understanding gene regulation and disease mechanisms. By combining NEB's enzyme innovation and reagent production with EpiCypher's chromatin biology expertise, the collaboration aims to deliver high-performance solutions that could set new standards in the field. This move aligns with broader industry trends toward multiomic workflows and advanced sequencing applications, potentially reshaping the epigenomics research landscape.
What we're watching
- Market Penetration
- Whether NEB can effectively expand EpiCypher's product reach in international markets beyond Germany and the UK.
- Technological Integration
- The pace at which the combined assay development and reagent expertise will yield breakthrough epigenomics tools.
- Competitive Positioning
- How this partnership will position NEB and EpiCypher against competitors in the epigenomics research space.
Related topics